Clinically significant prostate cancer is associated with high urine TMPRSS2-ERG levels based on Epstein criteria that stratify disease aggressiveness using PSA density and biopsy characteristics including the percentage of normal and tumor prostate tissue detected, Gleason score, and the number of tumor cores [27]. The gene discussed is TMPRSS2; the disease is prostate carcinoma.